

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.,
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884

PATENT OWNER'S PRELIMINARY RESPONSE

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. BACKGROUND	3
A. EYLEA®	3
1. Development of Eylea® for AMD	4
2. Development of Eylea® for DME	6
B. '572 Patent	7
C. Apotex Petition	8
D. District Court Litigation	10
III. PRIORITY DATE	12
IV. LEVEL OF ORDINARY SKILL IN THE ART	13
V. CLAIM CONSTRUCTION	13
A. The <i>Results Limitations</i> Have Patentable Weight	14
VI. THE BOARD SHOULD DENY INSTITUTION BECAUSE PETITIONER HAS NO REASONABLE LIKELIHOOD OF SUCCESS ON ANY GROUND	20
A. Ground II: The December 2010 Press Release Is Not Prior Art	22
1. The Invention Was Conceived and Reduced to Practice Before December 20, 2010	22
2. The December 2010 Press Release Discloses the Inventor's Own Work	25
B. Ground III: The November 2010 Press Release Is Not Prior Art	26
1. The Invention Was Conceived and Reduced to Practice Before November 22, 2010	26
2. The November 2010 Press Release Discloses the Inventor's Own Work	27
C. Ground IV: Dixon and the 2006 Press Release Do Not Disclose the Visual Acuity Results	28
D. Ground V	38

TABLE OF CONTENTS

(continued)

	Page
1. The 2009 Press Release, Dixon, and 2007 ARVO Abstract Do Not Disclose the Visual Acuity Results	39
2. The 2010 ARVO Abstract Is Not Prior Art	40
E. Ground VI	42
1. Dixon and the 2006 Press Release Do Not Disclose the Visual Acuity Results	42
2. The December 2010 Press Release Is Not Prior Art	42
F. Ground VII	43
1. The 2009 Press Release, Dixon, and 2007 ARVO Abstract Do Not Disclose the Visual Acuity Results	43
2. The 2010 ARVO Abstract Is Not Prior Art	43
3. The December 2010 Press Release Is Not Prior Art	43
G. Ground VIII	44
1. Dixon Does Not Disclose the Visual Acuity Results	44
2. The December 2010 Press Release Is Not Prior Art	44
H. Ground IX: The 2009 Press Release, Shams, and Elman 2010 Do Not Disclose Four Secondary Doses	44
I. Ground X: The <i>Results Limitations</i> Have Patentable Weight	47
J. Ground XI: The <i>Results Limitations</i> Have Patentable Weight	47
K. Ground I: The 2009 Press Release Does Not Disclose that the VEGF Antagonist Was Administered for the Purpose of Treating an Angiogenic Eye Disorder	48
VII. THE BOARD SHOULD DENY INSTITUTION UNDER <i>FINTIV</i> BECAUSE THE SAME CLAIMS AND ART ARE AT ISSUE IN DISTRICT COURT	49
A. <i>Fintiv</i> Factors One, Two, Three, Four, and Six Favor Denial	50
B. <i>Fintiv</i> Factor Five Does Not Outweigh the Other <i>Fintiv</i> Factors	53

TABLE OF CONTENTS
(continued)

	Page
VIII. THE BOARD SHOULD DENY INSTITUTION UNDER 35 U.S.C. § 325(D) BECAUSE THE EXAMINER AND BOARD REJECTED THE SAME ART AND ARGUMENTS.....	54
A. The Board Considered and Rejected the Art and Arguments.....	55
B. The Examiner Allowed the '572 Patent After Considering the Asserted Art.....	58
C. No Material Error	61

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>Advanced Bionics, LLC v. MED-EL Elektromedizinische Geräte GmbH</i> , IPR2019-01469, 2020 WL 740292 (P.T.A.B. Feb. 13, 2020)	55, 56, 58, 61
<i>Allergan Sales, LLC v. Sandoz, Inc.</i> , 935 F.3d 1379 (Fed. Cir. 2019)	14, 15, 18, 19
<i>Apotex Inc. v. Regeneron Pharmaceuticals, Inc.</i> , IPR2022-01524, Paper 9 (P.T.A.B. Mar. 10, 2023)	<i>passim</i>
<i>Apple Inc. v. Fintiv, Inc.</i> , IPR2020-00019, 2020 WL 2126495 (P.T.A.B. Mar. 20, 2020)	<i>passim</i>
<i>Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.</i> , 598 F.3d 1336 (Fed. Cir. 2010)	13
<i>Becton, Dickinson & Co. v. B. Braun Melsungen AG</i> , IPR2017-01586, 2017 WL 6405100 (P.T.A.B. Dec. 15, 2017)	55, 62
<i>In re Best</i> , 562 F.2d 1252 (C.C.P.A. 1977)	34
<i>Bristol-Myers Squibb v. Ben Venue Lab 'ys, Inc.</i> , 246 F.3d 1368 (Fed. Cir. 2001)	16, 17
<i>Comark Comm 'ns, Inc. v. Harris Corp.</i> , 156 F.3d 1182 (Fed. Cir. 1998)	18
<i>Commscope Techs. LLC v. Dali Wireless, Inc.</i> , IPR2022-01293, 2023 WL 2604001 (P.T.A.B. Mar. 9, 2023)	51
<i>Fitbit, Inc. v. Philips N. Am. LLC</i> , IPR2020-00828, 2020 WL 6470312 (P.T.A.B. Nov. 3, 2020)	54
<i>Foundation Medicine, Inc. v. Guardant Health, Inc.</i> , IPR2019-00636, Paper 10, 13 (P.T.A.B. Aug. 20, 2019)	34

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.